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Circulating tumor cells (CTCs) are rare and heterogeneous cells found in the peripheral blood 
of cancer patients. They are supposed to be a central component of metastatic dissemination and 
have been correlated with prognosis, progression-free survival, and treatment efficacy in different 
solid tumors (1, 2). Despite CTC significance, studies conducted on them still present considerable 
issues. In particular, regarding to how CTCs should be investigated and to their actual metastatic 
competence and tumor heterogeneity reflecting dissimilar cancer cell subpopulations. Importantly, 
CTCs’ clinical utility has not been demonstrated and they cannot be utilized to guide therapeutic 
decisions. As reviewed by others (3), recent and currently ongoing clinical trials are trying to deter-
mine the predictive role of CTCs, but they are apparently failing to support definitive conclusions. 
Nevertheless, the results of these trials could shed a light on the real possibilities of CTCs. In our 
opinion, CTC troubleshootings will depend on what scientific community will explore about CTCs 
and the metastatic process. Only a deeper insight in base knowledge about CTCs and their role in 
tumor biology may help us in overcoming such hurdles.
A huge amount of efforts have been made to solve these problems. In the last decade, a number 
of technical solutions have been evaluated to study CTCs. Based on biological and/or physical 
properties (4), each approach owns strengths and weaknesses. Up to now, the only device that has 
reached a major confirmation by clinical evidence is the  CELLSEARCH® System (5). Despite the 
pivotal results obtained with this system (6–9), its detection approach, based on epithelial markers 
only, fails to reflect all the potential CTC subpopulations, e.g., EpCAM-negative cells (10). Antigen-
independent approaches that allow the identification of EpCAM-negative cells also (11–13) could 
eliminate the risk of underestimation of the dissimilar CTC populations; however, it could increase 
the risk of unspecific selection (14). Although the lack in technical standardization still hinders 
CTCs’ full translation in the clinical practice, these alternative methods could shed a light on the 
true nature of CTCs and pave the way to a clearer window into cancer biology and metastasis. In 
our opinion, in order to get further key insights into tumor aggressiveness, metastatic competence, 
heterogeneity, and resistance to treatment, we have to look back more deeply at base research, i.e., 
CTC-related epithelial–mesenchymal transition and stemness, CTC subpopulation/heterogeneity, 
and to CTC preclinical ex vivo studies.
It seems reasonable that CTC subsets and progression of metastasis could be enabled by EMT or 
by an EMT-like process (15). However, the involvement of EMT in metastatic dissemination is still 
debated (16, 17). It has been observed that EMT is not always needed for tumor cell motility (13) and 
recently, EMT was reported to be dispensable for metastasis, while contributing to chemoresistance 
(18, 19). Notably, not all the steps of EMT are necessary to establish an invasive phenotype of cancer 
cells (14). It has been postulated that EMT could be connected to cancer stemness (20) and that CTC 
population may comprise a subset of cells, with self-renewal, multi-potency, and tumor-initiating 
capabilities. Taking together, these aspects suggest two current needs for the CTC-research field. 
First, a detection approach more comprehensive than those established so far, able to catch all the 
different CTC subpopulations. Second, the necessity of a more in-depth analysis into the EMT regu-
latory networks during cancer initiation and progression (21). This approach will likely reveal the 
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actual role of CTC subsets as “key players” involved in metastasis 
onset and progression (i.e., metastases-initiating CTCs), paving 
the way to innovative treatment regimens. Important technologi-
cal improvements achieved in the field of genetic, genomic and 
transcriptomic analysis, as whole genome amplification (WGA), 
whole transcriptome amplification (WTA) for single cell, digital 
PCR (dPCR), and next-generation sequencing (NGS), could help 
to improve CTC research field and have to be accurately taken 
into consideration. Serial CTC molecular tumor profiling can 
facilitate the detection of primary (22) or acquired mechanisms 
of resistance to therapy, such as the emergence of ESR1 muta-
tions in breast cancer or AR splicing variants in prostate cancer 
in response to targeted therapy (23, 24).
These last data indicate that monitoring regulatory networks 
and heterogeneity of CTCs, although still quite hampered by 
methodological issues, will offer significant clinical information 
about cancer progression, potential new therapeutic targets, and 
tumor sensitivity or resistance to therapy (25–29).
Circulating tumor cell population likely contains metastasis 
precursors, and their ex vivo culture represents a philosopher’s 
stone of translational-oncology research. Ex vivo culturing of 
CTCs may provide a powerful model of the metastatic cascade in 
basic research and a pivotal test for drug susceptibility/resistance 
in translational research (30).
In the last years, the CTC world’s leading groups had signed 
pioneering studies about ex vivo culturing of CTCs. Ex vivo 
CTC studies can be grouped as canonical in vitro culturing (11, 
13, 30) and mice-incubator investigations (31, 32). Long-term 
CTC in vitro culturing were performed for the first time by the 
Marchetti’s and Maheswaran’s labs (11, 30), from blood of meta-
static breast cancer patients. Zhang et al. detected and established 
CTC subpopulations targeted for brain metastases (11). These 
CTC cell lines were EpCAM negative, positive for a robust stem 
cell marker as ALDH1 and for Notch1, HER2, EGFR, and HPSE. 
Notably, CELLSEARCH® corresponding analyses revealed few 
or any “conventional” CTCs. Yu et al. generated CTC cell lines 
from consecutive single-patient blood draws (30). All the CTC 
cell lines were able to generate metastases in xenograft model 
proving their tumorigenic capability. Interestingly, both studies 
utilized a stem cell culture dedicated medium, strengthening the 
idea of the stem-like nature of CTCs. A CTC cell line was estab-
lished from a metastatic colon cancer patient also (33). These 
tumorigenic cells owned the chromosomal aberrations observed 
in the primary tumor and were positive for ALDH and CD133 
(stemness features).
A different ex vivo approach implied to expand CTCs into a 
xenograft model as a living “incubator.” This strategy consisted 
of a direct inoculation of enriched CTCs into immunodeficient 
mice without any in vitro passage. In an early study of Pretlow 
et al. (31), authors inoculated nucleated cells from 9 to 21 ml of 
blood from 14 treatment-refractory metastatic cancer patients 
(colon and prostate) into immunodepressed mice. Despite the 
lack of a CTC enrichment step, 3 out of 14 mice developed 
lung metastases. A more refined study was recently reported by 
Baccelli et  al. (32). In this study, erythrocytes deprived blood 
from 3 out of 110 metastatic cancer patients formed different 
metastases (lung, liver, and bone) in recipient mice. Hodgkinson 
et  al. (34) inoculated enriched CTCs in immunocompromised 
mice and established xenopatient models from six small-cell lung 
cancer patients. Xenopatient models mirrored patient responses 
to chemotherapy.
All these pioneering studies in ex vivo culturing of CTCs 
demonstrated how CTC basic research is important and neces-
sary, from discovering specific genetic signature of resistance to 
mirroring patient response to therapy. More studies, however, 
have to be undertaken to expand our knowledge on CTC and 
translate their promises from bench to bedside.
A further critical matter that should be clarified is how many 
CTCs detected in few milliliters of blood may be representative 
of all relevant genetic and phenotypic heterogeneity of cancer 
cell with metastatic aptitude. A robust increase in the volume of 
blood analyzed will advantageously raise the number of detected 
CTCs, enabling the study of a higher more representative and 
informative number of tumor cells (35, 36).
In conclusion, we think that future base research studies on 
CTCs will be pivotal to move forward this field of investigation 
at both the preclinical and clinical levels. In order to progress 
toward the clinical utility of CTCs, biological data and techno-
logical improvements should be kept in mind and thoughtfully 
considered. To unravel CTC biology and to demonstrate their 
clinical value, a fully comprehensive CTC analysis approaches 
have to be achieved.
These advanced analyses combine: larger screened blood 
volume followed by CTC functional studies and deep next- 
generation “-omic” analysis. These steps could unveil CTC genetic 
heterogeneity, markers of resistance to therapy and identify actual 
metastases initiating CTCs. A new explanation of CTC at cellular 
and molecular level in both early and metastatic cancer stages 
(37) is now mandatory.
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